Article & News

Gubba Group
‘Near-misses’ list to avert drug reac­tion

India aims to pre­vent poten­tially dan­ger­ous drug reac­tions before they reach patients, mov­ing bey­ond largely ret­ro­spect­ive report­ing towards pro­act­ive drug-safety mon­it­or­ing. Under a pro­posed frame­work,

Gubba Group
Indian pharma has little reason to fear Trump

Indian pharmaceutical firms have spent decades supplying American patients with affordable medicines. That dominance will be difficult to challenge, despite President Donald Trump’s threat to